Founded in 2019, Engrail is forging a new direction to reduce the enormous burden of diseases that impact the nervous system. We unite biological insights with clinically meaningful solutions to build and catalyze a diversified portfolio of transformative medicines. Harnessing our rigorous scientific approach to identify the most promising therapies, we leverage our flexible transaction model to advance assets with validated mechanisms and efficiently move them through development to commercialization.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/18/20 | $32,000,000 | Series A |
Nan Fung Life Sciences | undisclosed |
| 08/03/21 | $32,000,000 | Series A |
Nan Fung Life Sciences | undisclosed |
| 03/19/24 | $157,000,000 | Series B |
abrdn Eight Roads F-Prime Capital Partners Forbion Capital Partners Longwood Fund Norwest Venture Partners Pivotal Life Sciences Red Tree Venture Captial RiverVest Venture Partners Ysios Capital | undisclosed |
